Developing and Demonstrating Bioequivalence of Semi-Solid Dosage Forms

The US Food and Drug Administration (FDA) issued new draft guidance in December 2016 indicating that generic manufacturers can demonstrate bioequivalence for a specific semi-solid dosage form using predictive in vitro testing as a surrogate for in vivo testing. In this paper, we explain how bioequivalence can be achieved for generics in semi-solid dosage forms, including the role of in vitro release testing (IVRT) and in vitro permeation testing (IVPT).

"*" indicates required fields

First Name*

Last Name*

Company*

State*

Country

Email*

Phone*

Please only hit the submit button once.

I AGREE*

By submitting this form I agree that Frontage may process my data in the manner described in Frontage’s Privacy Policy.

Comments

This field is for validation purposes and should be left unchanged.

Developing and Demonstrating Bioequivalence of Semi-Solid Dosage Forms

Resources to Consider

Rapid, accurate and highly customizable assay platforms for...

ADC PK Profiling Strategies on LC-MS Platforms: Top-down,...